To assess whether the redox state of proteins in AML patients resistant to AZA reflects our observations in AML cell lines, we conducted redox proteomic profiling of CD34+ cells isolated from three patients at relapse following prior Vidaza treatment (4R, 5R, 6R) (Supplementary Table 3). The gene discussed is CD34; the disease is acute myeloid leukemia.